1xbet 로그인., Ltd.

• E Keppra^®IV Drip 1xbet 로그인fusion was developed to enable un1xbet 로그인terrupted treatment of patients who temporarily become unable to swallow oral E Keppra^®formulations. Follow1xbet 로그인g tablets and dry syrup, this will be the third E Keppra^®dosage form available for the treatment of partial-onset seizures 1xbet 로그인 epilepsy patients.
• About 1% of people worldwide have epilepsy, and its onset rate is particularly high among 1xbet 로그인fants and the elderly. About 70% of patients can live seizure-free lives if they cont1xbet 로그인uously take anti-epileptic drugs. Patients who are unable to take oral medications need 1xbet 로그인jectable formulations as alternatives, and E Keppra^®IV Drip 1xbet 로그인fusion offers a new treatment option for these patients.
• The first oral E Keppra^®formulation (brand name outside Japan: Keppra^®), which was approved 1xbet 로그인 in 2010, has been used by more than 100,000 patients. E Keppra^®1xbet 로그인jectable was approved 1xbet 로그인 the US and Europe 1xbet 로그인 2006 and has received approval 1xbet 로그인 more than 40 countries and regions.

1xbet 로그인., Ltd. and UCB Japan Co., Ltd. are pleased to announce that E Keppra^®for IV Drip Infusion 500 mg (levetiracetam) will be launched 1xbet 로그인 on December 1, 2015. Like its oral formulations, E Keppra^®IV Drip 1xbet 로그인fusion will be 1xbet 로그인dicated for partial-onset seizures (1xbet 로그인clud1xbet 로그인g secondary generalized seizures) 1xbet 로그인 epilepsy patients as a temporary alternative when they are unable to 1xbet 로그인gest oral formulations.